Avanir Pharms Drug Patent Portfolio
Avanir Pharms owns 1 orange book drug protected by 3 US patents Given below is the list of Avanir Pharms's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US7659282 | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | 13 Aug, 2026 | Active |
US8227484 | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | 17 Jul, 2023 | Expired |
USRE38115 | Dextromethorphan and an oxidase inhibitor for treating intractable conditions | 26 Jan, 2016 | Expired |
Latest Legal Activities on Avanir Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Avanir Pharms.
Activity | Date | Patent Number |
---|---|---|
Maintenance Fee Reminder Mailed
Critical
| 11 Mar, 2024 | US8227484 |
Payment of Maintenance Fee, 12th Year, Large Entity | 28 Jul, 2021 | US7659282 (Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 09 Jan, 2020 | US8227484 |
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 16 Oct, 2014 | US8227484 |
Recordation of Patent Grant Mailed
Critical
| 24 Jul, 2012 | US8227484 |
Patent Issue Date Used in PTA Calculation
Critical
| 24 Jul, 2012 | US8227484 |
Email Notification
Critical
| 05 Jul, 2012 | US8227484 |
Issue Notification Mailed
Critical
| 04 Jul, 2012 | US8227484 |
Email Notification
Critical
| 29 Jun, 2012 | US8227484 |
PG-Pub Issue Notification
Critical
| 28 Jun, 2012 | US8227484 |
Dispatch to FDC | 23 Jun, 2012 | US8227484 |
Application Is Considered Ready for Issue
Critical
| 13 Jun, 2012 | US8227484 |
Electronic Review
Critical
| 11 Jun, 2012 | US8227484 |
Mail Applicant Initiated Interview Summary | 11 Jun, 2012 | US8227484 |
Email Notification
Critical
| 11 Jun, 2012 | US8227484 |
Avanir Pharms's Family Patents
Avanir Pharms Drug List
Given below is the complete list of Avanir Pharms's drugs and the patents protecting them.
1. Nuedexta
Nuedexta is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US7659282 | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
13 Aug, 2026
(1 year, 7 months from now)
| Active |
US8227484 | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
17 Jul, 2023
(1 year, 5 months ago)
| Expired |
USRE38115 | Dextromethorphan and an oxidase inhibitor for treating intractable conditions |
26 Jan, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nuedexta's drug page